Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (16553)	3/5/1998 2:53:00 PM
From: Henry Niman	Read Replies (4) \| Respond to of 32384

Bernie, Do you recall who acquired ATHN? John Groome was the ATHN CEO and he now has a new title at the acquiring company (Elan?). He is on LGND's board (only GLYC board member to move onto LGND's board) and Athena was involved in the study that I uploaded. (Did DR give you any samples? This is a test to see if they work :-)

To: Flagrante Delictu who wrote (16553)	3/5/1998 3:02:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Time's Up :-) ELAN CORPORATION AND ATHENA NEUROSCIENCES STOCKHOLDERS APPROVE MERGER Dublin, Ireland and South San Francisco, June 27 - Elan Corporation, plc (NYSE: ELN) ("Elan") and Athena Neurosciences, Inc. (Nasdaq: ATHN) ("Athena") jointly announced that at special meetings held earlier today the stockholders of each company approved the planned merger of Elan and Athena. Under the merger agreement, which was announced March 18, 1996, Athena will become a wholly owned subsidiary of Elan. The merger creates a fully integrated drug delivery and biopharmaceutical company. Elan has capabilities in discovery, development, manufacturing, and sales and marketing. Donal J. Geaney, Elan's president and chief executive officer said, "This merger marks the fulfillment of our mind-to-market strategy. It provides the opportunity for us to capitalize on an important therapeutic niche, by combining Athena's leading Alzheimer's disease research program with Elan's established development expertise. Under the terms of the merger agreement, Athena's stockholders will receive 0.2956 Elan American Depositary Shares for each Common Share of Athena they own at the time the merger is completed. Elan and Athena expect the merger to be completed on July 1, 1996. Upon completion of the merger, Athena will continue to operate as Athena Neurosciences, Inc., and the company's headquarters will remain in South San Francisco. Elan Corporation, plc is a leading worldwide drug delivery company with innovative drug absorption technologies designed to improve patient care in a cost-effective manner. Its principal research and manufacturing facilities are in Ireland, the United States and Israel. Athena Neurosciences, Inc. was founded in 1986 to discover, develop and market products to be used primarily by neurologists for the treatment and diagnosis of neurological disorders. UNS Contact: Donal J. Geaney, President & Chief Executive Officer, or Thomas G. Lynch, Executive Vice President and Chief Financial Officer, both of Elan Corporation, plc, tel Ireland 00 353-1-709-4617 or John Groom, President & Chief Executive Officer, or Eric J. Liebler Director, External Relations, both of Athena Neurosciences, Inc., tel USA 00 1 415-877-0900

To: Flagrante Delictu who wrote (16553)	3/5/1998 3:04:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

ATHENA NEUROSCIENCES, INC. Who We Are and What We Do The need is real: Alzheimer's Disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, migraine, cerebral palsy and various other lesser-known conditions all affect the human neurological system, often with devastating consequences despite the best medical care available. It has been estimated that at any given time nearly 10% of the population is affected by neurological disease or injury. When neurological illness strikes, the neurologist is often at the front line providing patient clinical care. In the fight against neurological illness, Athena Neurosciences, Inc. is working to advance and improve the neurologist's medical arsenal. Athena, a wholly-owned subsidiary of Elan Corporation, plc, is a biopharmaceutical company headquartered in South San Francisco, California, that discovers, develops and markets therapeutic products and diagnostic services for people with neurological conditions. ATHENA DIAGNOSTICS: PROVIDING NEUROLOGISTS INFORMATION TO BETTER DIAGNOSE AND TREAT NEUROLOGICAL CONDITIONS, INCLUDING ALZHEIMER'S DISEASE Many neurological illnesses are difficult for neurologists to diagnose and treat. Athena Diagnostics is a reference laboratory offering physicians more than 50 different testing services that assist in clinical diagnosis and decision-making for a wide range of neurological disorders. Alzheimer's disease is notoriously difficult to diagnose. In March 1996, Athena Diagnostics introduced to physicians its Alzheimer's Disease Diagnosis Service. ATHENA RX HOME PHARMACY: PROVIDING COMPREHENSIVE PHARMACY SERVICES TO PEOPLE WITH NEUROLOGICAL CONDITIONS Athena Rx Home Pharmacy is a full-service, express delivery pharmacy specifically designed to serve the needs of people with neurological disorders. ATHENA'S RESEARCH: WORKING TO DISCOVER NEW TREATMENTS FOR NEUROLOGICAL DISEASES Athena and its corporate partners have established leading research programs that aim to discover new treatments for Alzheimer's disease, multiple sclerosis and other neurological diseases. Athena, in collaboration with Eli Lilly and Company, has made significant advances in Alzheimer's disease research. The development of a proprietary transgenic mouse model for Alzheimer's disease should enable Athena researchers to screen for potential therapies for the disease. Athena's Alzheimer's disease research program focuses on the role of a protein known as beta-amyloid peptide, the main constituent of plaque deposits found in the Alzheimer's brain. Athena scientists believe that beta-amyloid peptide plays a central role in the Alzheimer's disease process, and they are working to identify compounds that either inhibit beta-amyloid peptide production or mitigate its effects. DEVELOPING NEW THERAPIES THAT BENEFIT PEOPLE WITH NEUROLOGICAL CONDITIONS Athena is currently conducting clinical trials with new drug therapies for multiple sclerosis, cervical dystonia, epileptic seizures and spasticity associated with multiple sclerosis or spinal cord injury. The U.S. Food and Drug Administration has, in recent months, approved two Athena products, Zanaflex and Diastat. Additionally, a new diagnostic test NAbFeron has been added in the Diagnostics Division. WHERE WE ARE LOCATED Corporate Headquarters Athena Neurosciences, Inc. 800 Gateway Boulevard South San Francisco, California 94080 Telephone: 650-877-0900 Fax: 650-877-8370 E-mail:calmonte@msn.com Athena Rx Home Pharmacy 800 Gateway Boulevard South San Francisco, California 94080 Telephone: 800-5ATHENA (800-528-4362) Fax: 650-877-7433 Athena Diagnostics, Inc.* Four Biotech Park 377 Plantation Street Worcester, MA 01605 Telephone: 508-756-2886 Telephone: 800-394-4493 Fax: 508-753-5601 Athena Neurosciences (Europe) Ltd.* 1 Meadway Court Rutherford Close Stevenage, Herts SG1 2EF United Kingdom Telephone: 44-1438-730200 Fax: 44-1438-741452 *wholly-owned subsidiaries of Athena Neurosciences, Inc.